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Abstract 
Abstract 
Introduction: Veno-venous extracorporeal membrane oxygenation (VV ECMO) is an indicated treatment 
for severe acute respiratory distress syndrome (ARDS) refractory to conventional medical treatment. 
Severe ARDS is a common complication of CoVID-19 infection. Subsequently, the efficacy of VV ECMO in 
CoVID-19 severe ARDS patients must be investigated. ECMO is a resource-intensive treatment modality, 
meaning that its use must be reserved for patients with robust indications and paucity of 
contraindications. 
Methods: We performed retrospective chart review of three patients at the University of Nebraska Medical 
Center that were placed on VV ECMO secondary to severe ARDS from CoVID-19 infection. 
Results: All patients were male with a median age of 39 years. Two patients were of Hispanic descent, 
and the third was of Asian descent. No patients had underlying lung disease, and all patients had type II 
diabetes mellitus. Median time on mechanical ventilation prior to ECMO cannulation was six days. 
Median duration of ECMO treatment was 21 days with a range of 17 to 27 days. All patients were 
decannulated from ECMO during their hospital stay, and all patients survived to 60 days post-hospital 
discharge. Complications while on ECMO included GI bleeding in two patients, hematuria in one patient, 
necessitation of vasodilator and vasopressor support in all patients, AKI in two patients, secondary 
bacterial pneumonia in two patients, and blood cultures positive for gram-positive organisms in all 
patients. No patients suffered DVT or CVA. All patients required pRBC transfusion during ECMO 
treatment. Two patients were treated with remdesivir and one patient received baricitinib, a JAK-inhibitor. 
Conclusion: VV ECMO is a viable treatment for patients with severe ARDS secondary to CoVID-19 
infection that have failed conventional therapy. Stringent adherence to inclusion and exclusion criteria is 
imperative. VV ECMO combined with lung protective ventilation strategies with a focus on minimizing 
driving pressure can provide life-saving treatment to patients with severe ARDS secondary to CoVID-19 
infection 
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Abstract
treatment for severe acute respiratory distress 
syndrome (ARDS) refractory to conventional 
medical treatment. Severe ARDS is a common 
must be investigated. ECMO is a resource-
intensive treatment modality, meaning that its 
use must be reserved for patients with robust 
indications and paucity of contraindications.
We performed a retrospective chart review of 
three patients at the University of Nebraska 
ECMO secondary to severe ARDS from 
with a median age of 39 years. Two patients 
were of Hispanic descent, and the third was 
of Asian descent. No patients had underlying 
diabetes mellitus. Median time on mechanical 
ventilation prior to ECMO cannulation was 
six days. Median duration of ECMO treatment 
was 21 days with a range of 17 to 27 days. 
All patients were decannulated from ECMO 
during their hospital stay, and all patients 
survived to 60 days post-hospital discharge. 
Complications while on ECMO included 
one patient, necessitation of vasodilator and 
two patients, secondary bacterial pneumonia 
in two patients, and blood cultures positive 
for gram-positive organisms in all patients. 
patients required pRBC transfusion during 
ECMO treatment. Two patients were treated 
with remdesivir and one patient received 
a viable treatment for patients with severe 
have failed conventional therapy. Stringent 
adherence to inclusion and exclusion criteria 
protective ventilation strategies with a focus 
on minimizing driving pressure can provide 
life-saving treatment to patients with severe 
Introduction
As of March 2021, there have been 124 
with more than 540,000 deaths.1 Between 
March 1, 2020, and August 16, 2020, the 
U.S. experienced 260,000 more deaths than 
2 Peak 
daily hospital admissions of patients with 
over 18,000 in early January 2021.3 Twenty 
percent of hospitalized patients in New York 
ventilation.4
Extracorporeal membrane oxygenation 
(ECMO) is a viable treatment for severe acute 
respiratory distress syndrome (ARDS) due to 
most common modality of extracorporeal 
support used for severe respiratory failure 
not amenable to medical interventions.5
ECMO is a device that replaces native lung 
function in situations of severe pulmonary 
by utilizing a membrane lung to provide 
oxygen and remove carbon dioxide, then 
returning oxygenated blood back to the 
can provide surrogate pulmonary and cardiac 
function. At many medical institutions, 
to treat patients with severe ARDS, bacterial 
or viral pneumonia, status asthmaticus, 
transplantation for individual patients and can 
be used as a temporizing measure in post-
operative patients experiencing respiratory 
failure.6,7 By facilitating lung-protective 
term lung injury by minimizing barotrauma, 
volutrauma, atelectrauma, and oxygen toxicity 
during recovery.7 Fig. 1 below provides a 
depiction of the ECMO circuit.
The inclusion criteria for ECMO vary by 
institution. One standard measure is the 
Murray Lung score. Scores above 2.5-3 
are commonly used to indicate the need 
for ECMO.  Uncompensated hypercapnia 
with an arterial blood gas pH <7.20 is 
another common indication.  A 2018 study 
described in Table 1.9 The Extracorporeal 
Life Support Organization (ELSO) has 
provided guidelines for ECMO indications 
and contraindications as well as special 
considerations for management (Table 2). 
many institutions worldwide when deciding if 
a patient is a candidate for ECMO. Common 
contraindications to the use of ECMO include 
Figure 1.
ECMO support. Blood is drained from the patient at the level of the IVC and returned to the level of the 
right atrium. Image courtesy of Dan Johnson, MD. Used with permission.
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end-stage pulmonary disease, multi-system 
organ failure, ineligibility for transplantation, 
morbid obesity, intracranial bleeding, 
contraindications to systemic anti-coagulation, 
ventilation (usually > 7 days), and age > 65 
years.
Case
Three patients at our center have been placed 
patients were male with a median age of 
m2. Two patients were of Hispanic descent, 
while the third was of Asian descent. Pre-
diabetes mellitus in all patients, one patient 
with hypothyroidism, and one patient with 
a history of pericarditis in 2018. No patients 
had a history of lung disease or tobacco 
are shown in Table 3 below. These criteria 
were developed in response to the increased 
certain risk factors including age > 65, male 
gender, obesity, hypertension, COPD, diabetes 
mellitus, malignancy, and cardiac disease.
with hypoxia (P/F ratio <100), while two 
patients were initiated due to combined 
hypoxia (P/F <150) and hypercapnia. No 
patients received nitric oxide or bicarbonate 
infusion prior to ECMO. Prior to ECMO 
cannulation, all patients received maximal 
medical therapy including neuromuscular 
blockade, prone positioning, inhaled 
epoprostenol, and maximal lung protective 
mechanical ventilation settings. Femoral-
femoral venovenous cannulation was 
performed for each patient at the bedside. 
Ultrasound guidance was used, along with 
standard Seldinger technique, for venous 
access. Serial dilation was then performed 
via ultrasonography and chest/abdomen 
radiographs. Fig. 2 shows a chest radiograph 
of proper ECMO cannula placement.
The median time on mechanical ventilation 
before ECMO initiation was six days. The 
mechanical ventilation mode utilized was 
for all patients prior to ECMO initiation. 
allows close monitoring of airway pressures. 
Lung protective strategies that emphasize low 
tidal volumes and low driving pressure are 
fundamental strategies to avoid barotrauma 
and volutrauma in these patients. Driving 
PEEP. Driving pressure less than 14 cm 
H2O is associated with increased ARDS 
survival.10,11
of Medicine (NEJM) article recently showed 
a linear relationship between changes in 
driving pressure and plasma concentrations of 
, 
and others.12 
All patients were successfully decannulated 
from ECMO during their hospital stay. The 
median duration of ECMO treatment was 21 
days with the shortest duration being 17 days 
and the longest being 27 days. Median length 
of hospital stay after decannulation was 24 
days. Median length of hospitalization was 47 
Survival at hospital discharge and 60 days 
post-hospital discharge were 100%.
Two patients experienced gastro-intestinal 
bleeding during treatment on ECMO, with 
one patient requiring partial bowel resection. 
One patient developed hematuria. All patients 
required red blood cell transfusions, with a 
median of 17 units during ECMO therapy. 
One patient also required transfusion of 3 
units of platelets, 2 units of fresh frozen 
plasma (FFP), and 10 units of cryoprecipitate. 
All three patients required vasodilators and 
vasopressors during their treatment. One 
Table 2.
Indications and Contraindications to placement onto ECMO. P/F: ratio of PaO2 to FiO2.
Indications for ECMO 1. Mortality risk > 80%
2. P/F < 80 with FiO2 > 0.90
3. Murray Lung Score of 3-4
Consideration for ECMO 1. Mortality risk > 50%
2. P/F < 150 with FiO2 > 0.90
3. Murray Lung Score of 2-3
Contraindications to ECMO 1. Conditions incompatible with normal life
2. Pre-existing conditions affecting quality of life
a. CNS status
b. End stage malignancy
c. Risk of systemic bleeding with anticoagulation
3. Age>65
4. Futility
a. Patients who are too sick (ie. Immunosuppression)
b. Have been on conventional therapy too long  
(Mechanical ventilation > 7 days)
Table 3.
Inclusion criteria used at UNMC for placement onto VV ECMO for ARDS secondary to SARS-CoV-2 
disease.
1. P/F ratio of less than 100 despite aggressive mechanical ventilation including FiO2 of 1.0, PEEP greater 
than 16, neuromuscular blockade, +/- prone.
2. Elevated peak airway pressures (greater than 40 mmHg) and/or plateau airway pressures (greater than 30 
mmHg) despite lung protective mechanical ventilation and maximal medical therapy.
3. pH of 7.2 or less with inability to correct respiratory acidosis with aggressive mechanical ventilation.
4. PaCO2 of 50 or greater despite maximal medical therapy, aggressive mechanical ventilation, and 
respiratory rate greater than or equal to 30 breaths per minute.
5. Mechanical ventilation performed for 3-7 days
6. Can accept patients on mechanical ventilation over 7 days on a case-by-case basis after review and 
agreement by all teams.
Table 1.
Respiratory and ventilator parameters that qualify for VV ECMO. 
1. PaO2:FiO2 <50 mmHg for >3 hours
2. PaO2:FiO2 <80 mmHg for >6 hours
3. Arterial blood pH <7.25 with a PaCO2 >60 mmHg for >6 hours 
and RR of 35 bpm 
and plateau pressure <32 cm of H2O
 and FiO2 >0.8
 and Tidal Volume 6 mL/kg
 and PEEP >10 cm of H2O
PaO2: arterial oxygen partial pressure; FiO2: fraction of inspired oxygen; PaCO2: arterial carbon dioxide 
partial pressure; RR: respiratory rate; PEEP: positive end-expiratory pressure
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patient required inotropic agents, and one 
required two minutes of CPR before ROSC 
after a tracheostomy change. Two patients 
suffered acute kidney injuries, with one 
requiring 17 days of continuous venovenous 
hemodialysis. Pneumothorax was seen in two 
patients. Two patients developed secondary 
bacterial pneumonia, while all three patients 
had blood cultures displaying gram-positive 
organisms. A positive urine culture was 
seen in one patient. Fig. 3 depicts these 
complications.
Two patients were treated with remdesivir 
and one received barcitinib, a JAK-inhibitor. 
Prone position was not used while on ECMO. 
One patient was discharged home, and two 
were discharged to long term acute care. 
Sixty-day survival after hospital discharge 
was 100% in our patient population. All 
patients required tracheostomies during their 
hospitalization. Of note, one patient was able 
to be decannulated from their tracheostomy 
prior to hospital discharge.
All of our patients (100%) in this case series 
and 60 days post-hospital discharge. One 
study with a larger patient population with any 
ARDS etiology displayed survival to ECMO 
6 Median duration 
of ECMO in the said study was 191 hours, 
while ours was 21 days (504 hours).6 Our 
patients spent a median time of 47 days in the 
hospital, compared to 16 days in the England 
study.5,6
patients was 67% compared to an incidence 
of 10.4% at other centers.6 Sixty seven of our 
patients developed culture-proven bacterial 
pneumonia, and 100% developed culture-
proven bloodstream infections. Culture 
proven infection occurred in only 15% of 
patients in the England study.6 A NEJM study 
in the introduction) placed on ECMO to a 
control group that only received standard 
treatment. Sixty-day survival in the ECMO 
group was 65% compared to 54% in the 
control group.9 The ECMO group had a 
higher incidence of bleeding events requiring 
transfusion and severe thrombocytopenia, but 
had fewer ischemic stroke cases.9 All patients 
in our study required RBC transfusion at some 
point during their care. Similarly, no patients 
treatment. All our patients had underlying 
dysfunctional pulmonary system in patients 
with severe ARDS, allowing time for lung 
recovery. Lung recovery is most effectively 
minimize barotrauma and volutrauma. 
is associated with increased survival and Figure 2. Chest x-ray showing diffuse pulmonary opacities consistent with SARS-CoV-2 infection.
Figure 3. List and number of patients suffering from complications related to or a consequence of ECMO therapy.
Number of Patients Experiencing Listed Complication
Complications on ECMO
0 1 2 3
Hematuria
GI Bleed****
Anemia Requiring RBC Transfusion***
DVT
CVA
Extremes of Blood Pressures Requiring Vasopressor or...
Cardiac Arrest Requiring CPR**




Blood Cultures Positive for Gram-Positive Organisms
Positive Urine Culture
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patients.10-12 At the University of Nebraska 
Medical Center (UNMC), our standardized 
mL/kg of predicted body weight, pressure-
settings, PEEP of 8-16 cm H2O, RR <10 bpm, 
plateau pressure < 30 mmHg, and driving 
pressure < 15 mmHg if able. These protocols 
not only give our patients the greatest chance 
of survival, but also help to reduce long-
term complications caused by high airway 
pressures.
Conclusion
powerful, but resource-consuming treatment 
modality for patients suffering from severe 
ARDS. A robust study in England reported 
respiratory failure secondary to numerous 
6 Another 
substantial study showed 90-day in-hospital 
patients suffering severe ARDS secondary to 
cases of severe ARDS.5 Sixty day survival in 
our patient cohort was 100%, displaying the 
An important theme in the study of treating 
of patients and use of strict mechanical 
ventilation strategies to minimize further 
lung damage. ECMO is a resource-intensive 
treatment that serves only as a bridge to 
recovery or transplant. Therefore, careful 
selection of patients with high likelihood 
of recovery is necessary. Contraindications 
for the practical and effective use of this 
treatment modality include, but are not 
limited to, end organ failure, minimal hope 
of recovery after decannulation, age >65, 
advanced cancer diagnosis, morbid obesity, 
and recent intracranial pathology. This careful 
utilization of resources is essential to the 
success of the treatment and patient outcomes.
induced severe ARDS. However, especially 
in pandemic times and the resulting limitation 
in resources, increased selectivity and strict 
adherence to protocols are necessary to 
results in longer duration of ECMO, a longer 
hospitalization than other causes of severe 
ARDS. 
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